Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|RTOG-1005||RTOG||A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1010||RTOG||A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1016||RTOG||Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1112||RTOG||Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1115||RTOG||Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 For Men with High Risk Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1216||RTOG||Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1308||RTOG||Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy For Inoperable Stage II-IIIB NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-BR-0118||RTOG||A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy For Multiple Brain Metastases||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-P-0011||RTOG||Phase III Randomized Study of Adjuvant Therapy For High Risk PT2-3N0 Prostate Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-P-0014||RTOG||A Phase III Randomized Study of Patients With High Risk; Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade with Delayed Chemotherapy" Study Closed and Terminated||Adult CIRB - Late Phase Emphasis||Completed|